SPDR S&P BIOTECH ETF (XBI)
| Assets | $5.93B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 64.08M |
| Dividend (ttm) | $0.13 |
| Dividend Yield | 0.14% |
| Ex-Dividend Date | Dec 23, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | -0.74% |
| Volume | 8,748,974 |
| Open | 93.50 |
| Previous Close | 92.72 |
| Day's Range | 91.54 - 93.86 |
| 52-Week Low | 81.14 |
| 52-Week High | 105.47 |
| Beta | 0.93 |
| Holdings | 143 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe SPDR S&P BIOTECH ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
24.85% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 2.79% |
| AbbVie Inc. | ABBV | 2.70% |
| Insmed Incorporated | INSM | 2.64% |
| Amgen Inc. | AMGN | 2.55% |
| BioMarin Pharmaceutical Inc. | BMRN | 2.44% |
| Vertex Pharmaceuticals Incorporated | VRTX | 2.40% |
| United Therapeutics Corporation | UTHR | 2.37% |
| Natera, Inc. | NTRA | 2.35% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.31% |
| Incyte Corporation | INCY | 2.30% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2024 | $0.00269 | Dec 26, 2024 |
| Sep 23, 2024 | $0.01523 | Sep 25, 2024 |
| Jun 24, 2024 | $0.11478 | Jun 26, 2024 |
| Dec 18, 2023 | $0.01388 | Dec 21, 2023 |
| Jun 20, 2023 | $0.00262 | Jun 23, 2023 |
| Mar 22, 2021 | $0.040 | Mar 25, 2021 |
News
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months
Can Health Care ETFs Aid Your Portfolio?
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's perfor...
XBI: Diverse Holding Amid Strong Catalysts, Buy
SPDR® S&P Biotech ETF is a strong investment due to rising demand for biotech solutions addressing chronic diseases and its diverse, equal-weighted portfolio. XBI's equal-weighting strategy reduces co...
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Healthcare Stocks: 2025 Outlook
I forecast healthcare stocks, especially biopharmaceuticals, to outperform the general averages due to four key investment themes. US healthcare expenditures are expected to grow at an annualized rate...
Trade Tracker: Joe Terranova buys the XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss why he's buying the Biotech ETF.
Final Trade: LNG, XLP, X, XBI
The final trades of the day with CNBC's Dominic Chu and the Fast Money traders.
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thu...
Finding Winners In Biotech, Probably The Riskiest Sector
Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year c...
Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)
Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA. Concerns about Mr. Kennedy leadin...
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
XBI: Biotech ETF Is A Must Have
SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the Russel...
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu...
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin...
XBI Is Breaking Out And Likely To Outperform In The Near Term (Technical Analysis)
Biotechnology equities have underperformed since late 2020, but recent acquisitions and drug approvals suggest a potential industry revaluation. SPDR S&P Biotech ETF (XBI) offers broad exposure to the...
Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.
Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.
Trade Tracker: Joe Terranova sells the ITA and XBI
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's selling these two ETFs.
Biopharmaceutical Stocks: The Next Phase Of The Rally Appears To Be Underway
Stock valuations in the pharmaceutical industry are becoming more attractive for potential mergers due to declining IPO prices. Aging population and prevalence of chronic diseases are driving favorabl...
Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross
Michelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.
Bond ETFs attract record flows in July as investors position for Fed rate cuts
Hello! Bonds seemed more appealing to ETF investors than ever before in July, based on flow data from State Street. This week's ETF Wrap looks at what's driving investors' appetite for fixed income la...